3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
10
Urinary Incontinence
2
Sexual Dysfunction, Physiological
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
31
Nivolumab
12
Cyclophosphamide
10
fludarabine
9
aldesleukin
8
atezolizumab
7
durvalumab
6
Magnetic Resonance Spectroscopy
6
Trastuzumab
5
Specimen Handling
5
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
Biopsy
5
fludarabine phosphate
4
Radiotherapy
4
Interleukin-2
4
Gene Expression Profiling
4
Carboplatin
4
tisotumab vedotin
3
cemiplimab
3
aflibercept
3
Polymerase Chain Reaction
3
Immunoglobulin G
3
Early Intervention, Educational
3
Cisplatin
3
Bevacizumab
3
tremelimumab
2
tislelizumab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Genitourinary
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled